S905
Clinical - Mixed sites & palliation
ESTRO 2026
hyperthermia combined with RT (dHT+RT) in patients with recurrent and treatment-refractory bulky tumours. Material/Methods: Patients treated with palliative dHT+RT at our institution from August 2022 until October 2025 were retrospectively reviewed. Inclusion criteria comprised:(i) dHT+RT with 40 Gy in 16 fractions, (ii) baseline GTV >200cc, and (iii) at least two follow-up CTs. Radiative dHT was applied with the ALBA4D system (Med-Logix, Italy). Results: Thirteen patients (median age 58, range44–79) with recurrent abdominopelvic tumors were treated with palliative intent of which 46% (6/13) had an ECOG performance status of 2–3. The mean/median GTV was 1553/1015 cc (range 215–5169) and soft tissue sarcoma was the predominant histology (46%, 6/13). Prior surgery was documented in 38% (5/13) of patients and 54% (7/13) had received ≥ 2 lines of systemic therapy. Tumors were predominantly cystic (23%,3/13), involved critical OARs (31%,4/13) and 77% (10/13) presented with metastatic disease. A median of six deep hyperthermia (dHT) sessions was administered per patient (range 2–7). Mean/median follow-up was 13.1/11.4 months (range 3.9–28.5). A partial volumetric response (PR) (>30% volume reduction) was observed in 69% (9/13) of patients with a mean/median tumour volume reduction of 53%/57% (range, 100% to –9%) (FIG).Three patients demonstrated stable disease (<30% volume reduction) and patient 8, with the largest and completly cystic tumour, had progressive disease. All four patients with only stable or progressive disease had large-volume sarcomas (1780–5169cc), including two with predominantly cystic morphology.Tumor-related pain was reported in 92% (12/13) of patients, with 83% (10/12) experiencing symptomatic relief after treatment. One grade 3 upper gastrointestinal bleeding occurred at a site of gastric tumour infiltration, related to either treatment side effects or tumour response. The 6-month and 1-year OS were 83.9% and 46.6%, the 6-month and 1-year freedom from local progression rates were 84.6% and 42.3%, respectively. Out of 10 deaths, 4 (40%) died due to local and 6 (60%) due to distant progression.
Conclusion: Moderate hypofractionated dHT+RT is safe and effective in achieving symptomatic and local responses in patients with recurrent, treatment-refractory bulky tumours. Poorer responses were associated with large sarcomas and predominantly cystic lesions, suggesting these may represent negative predictive factors. These findings are promising but warrant validation in larger patient cohorts. Keywords: Hyperthermia, bulky tumors Hospitalization Profile and Clinical Characteristics of Patients Admitted to a Dedicated Radiation Oncology Unit Alberto Fernández Romero 1 , Gloria Guardia 1,2 , Elena Gomez Duque 1 , Gloria Sánchez Naranjo 1 , Laura Fernández Banda 1 , Jose Luis González Cuartero 1 , Luz Fiorella Huertas Campos 1 , Juan Pablo Kim Kim 1 , Alba Delgado Domíngez 1 , Pablo Alcaide Córdoba 1 , Mariana Temes Ramos 1 , Fernando García Luque 1 , María Ángeles Perez Escutia 1 Digital Poster Highlight 3734 1 Radiation Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain. 2 Radiation Oncology, Genesis Care, Madrid, Spain
Purpose/Objective: Hospitalization in radiation oncology units is
uncommon because most treatments are provided on an outpatient basis. A specialized inpatient unit allows management of patients with high clinical complexity before, during, or after radiotherapy, ensuring continuous and multidisciplinary care. However, evidence describing patient characteristics and
Made with FlippingBook - Share PDF online